by Raynovich Rod | Jun 11, 2017 | Biopharmaceuticals
June 15-Update 2 after close…Biotechs Down with Techs-Red Screen Day Very few winners today: IBB down 0.77%, XBI down 1.36% to $71.55 near 52 week high of $73. ABBV near new highs at $70.60, BLUE up 24.7% for past month. EPZM soars 17% on EZH2 inhibitor, RXDX up...
by Raynovich Rod | May 26, 2017 | Biopharmaceuticals
Biotech Fades with Profit Taking: Is the pre-ASCO Momentum Gone? Technicals Matter Drug Pricing Scrutiny Continues Biotechs faded today now that the rush of oncology drug news slowed down. NASDAQ retained momentum with the ETF leader QQQ up 19% YTD pulling ahead of...
by Raynovich Rod | Apr 25, 2017 | 2025 Rayno Biopharmaceuticals Portfolio
Update #2 Large Cap Biopharmaceuticals: ABBV, ALXN, BMY, CELG Abbvie (ABBV) Reported Better than Expected Earnings and Revenues Worldwide GAAP revenues were $6.538B up 10.1% with Global Humira sales up 15.1% and Q1 IMBRUVICA sales of $551M. Full Year 2017 outlook for...
by Raynovich Rod | Oct 26, 2016 | Biopharmaceuticals, Macro
Update-3… 10/28 9:30 am… No Relief From Earnings- Biotech Stocks Get Crushed By More Pricing Commentary on Earnings Calls Amgen (AMGN) down 11% on pipeline, revenue growth, Enbrel pricing concerns despite beat. Softer pricing environment from McKesson...
by Raynovich Rod | Sep 26, 2016 | Biopharmaceuticals
Update-2… 9/29 Caution on Biotech-Major Sell-Off with IBB off 3.12% The market had a bad day today hit by Wells Fargo (WFC) Congressional hearings and paranoia about Deutsche Bank AG (DB). Unrelated to this news was a major sell-off in biotech stocks with...
by Raynovich Rod | Jun 29, 2016 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Update-2 …6/30 after the close Biotech stocks rallied again for the third day but momentum ebbed. Large caps were mainly in the green led by Alexion Pharmaceuticals (ALXN), Roche Holding (RHHBY) and Gilead Sciences (GILD). Mid-caps were mixed and well below...
by Raynovich Rod | Apr 8, 2016 | Biopharmaceuticals, Macro
Biotech Rally Loses Momentum But Still Up for the Week IBB up 3.37 % , XBI up 5.04% , XLV up 0.77% this week. Investors took profits today despite all of the media focus and renewed excitement for the long term potential of new blockbuster drugs. The rally began...
by Raynovich Rod | Jan 8, 2016 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Large Cap Biopharmaceutical Stock Valuations After Correction We previously summarized the Rayno Mid and Small Cap Portfolios for 2015, a good year despite the correction. With this post we summarized selected Sales and Earnings metrics (Source finviz.com) of...
by Raynovich Rod | Dec 3, 2015 | Biopharmaceuticals, Macro
Biotech Sell-Off Stops Bear Market Rally After a strong November and a rally from October lows biotech stocks broke down today along with the overall market. Keep in mind that it has been a bear market rally with expectations of a seasonal move up. There are plenty of...
by Raynovich Rod | Nov 19, 2015 | 2024 Rayno Tools and Diagnostics Portfolio, 2024-25 Life Science Portfolios, 2025 Rayno Biopharmaceuticals Portfolio
Update-1 Rayno Recap for week of 11/20/15 IBB up 3.04%, XBI up 1.92%, XLV up 2.82% Notable Small Cap Winners Curis (CRIS) up 4.13%, Fibrocell Sciences (FCSC) up 3.42%, Geron (GERN) up 4.82%, Ignyta (RXDX) up 37.39%, and Ocera Therapeutics (OCRX) up 5.31%. Notable...
